Amy Mcbride Wendell Sells 43,684 Shares of AxoGen (NASDAQ:AXGN) Stock

AxoGen, Inc. (NASDAQ:AXGN) Director Amy Mcbride Wendell sold 43,684 shares of AxoGen stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $29.31, for a total value of $1,280,378.04. Following the completion of the sale, the director directly owned 93,826 shares in the company, valued at approximately $2,750,040.06. This represents a 31.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

AxoGen Trading Up 1.0%

NASDAQ:AXGN opened at $31.70 on Friday. The company has a market cap of $1.46 billion, a P/E ratio of -634.00 and a beta of 1.06. AxoGen, Inc. has a twelve month low of $9.22 and a twelve month high of $34.24. The business has a 50 day moving average price of $24.39 and a two-hundred day moving average price of $17.45. The company has a quick ratio of 2.64, a current ratio of 4.09 and a debt-to-equity ratio of 0.54.

AxoGen (NASDAQ:AXGN) last posted its quarterly earnings data on Wednesday, October 29th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.03. The company had revenue of $60.08 million for the quarter, compared to the consensus estimate of $56.90 million. AxoGen had a negative net margin of 0.98% and a negative return on equity of 1.90%. As a group, analysts expect that AxoGen, Inc. will post -0.29 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of AxoGen in a research note on Monday. Citizens Jmp increased their price target on AxoGen from $26.00 to $34.00 and gave the company a “market outperform” rating in a research report on Thursday, October 30th. JMP Securities set a $34.00 price target on AxoGen in a research note on Thursday, October 30th. Citigroup reaffirmed a “market outperform” rating on shares of AxoGen in a research report on Thursday, October 30th. Finally, Lake Street Capital increased their price objective on AxoGen from $30.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, December 4th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, AxoGen presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.56.

Institutional Trading of AxoGen

A number of hedge funds have recently made changes to their positions in the business. Future Financial Wealth Managment LLC acquired a new position in shares of AxoGen during the 3rd quarter worth approximately $27,000. Aquatic Capital Management LLC lifted its holdings in AxoGen by 287.8% during the 3rd quarter. Aquatic Capital Management LLC now owns 1,710 shares of the medical equipment provider’s stock valued at $31,000 after purchasing an additional 1,269 shares during the last quarter. State of Alaska Department of Revenue bought a new position in AxoGen during the third quarter worth $43,000. Tower Research Capital LLC TRC increased its holdings in shares of AxoGen by 189.9% in the second quarter. Tower Research Capital LLC TRC now owns 5,079 shares of the medical equipment provider’s stock valued at $55,000 after purchasing an additional 3,327 shares during the last quarter. Finally, FNY Investment Advisers LLC bought a new position in shares of AxoGen in the third quarter valued at about $64,000. 80.29% of the stock is owned by institutional investors and hedge funds.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.